Last updated: February 12, 2026
Overview of the Drug
NDC 53746-0249 refers to Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb. It treats various cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, and others.
Current Market Position
- Market Launch & Indications: Approved since 2014, expanded use across multiple tumor types.
- Sales Data: In 2022, global sales surpassed $8 billion, with the U.S. accounting for approximately 65% of revenue.
- Competition: Key competitors include Merck’s Keytruda (pembrolizumab), AstraZeneca’s Imfinzi (durvalumab), and newer agents in the PD-1/PD-L1 class.
- Pricing: The average list price for nivolumab per 40 mg dose ranges from $3,200 to $3,500.
Pricing Considerations
- Average Wholesale Price (AWP): Approximate AWP for a 240 mg dose (standard dosing every 2 or 4 weeks) is roughly $27,000–$28,000 per administration.
- Reimbursement: Payers often negotiate discounts; net prices may be 25–35% lower than list prices.
- Cost-Effectiveness: In oncology, nivolumab is considered cost-effective within many payers’ thresholds, but the high price limits access in some markets.
Market Drivers and Constraints
Drivers:
- Expanding indications increase the market size.
- Regulatory approvals in multiple countries.
- Combination therapy approvals with agents like ipilimumab.
- Patient demand for immunotherapy options.
Constraints:
- Pricing pressures from payers and governments.
- Patent expirations for key indications (e.g., melanoma in 2024–2025), risking biosimilar entry.
- Cost-containment measures pursued by healthcare systems.
Price Projections (2023–2028)
Assuming steady market growth driven by new indications and broader adoption:
| Year |
Expected Global Sales |
Average Price per Dose |
Notes |
| 2023 |
$8.4 billion |
$3,200–$3,500 |
Current sales stabilize; increased competition may exert downward pressure. |
| 2024 |
$9.2 billion |
$3,100–$3,400 |
Patent expiration begins in key markets; biosimilars enter. |
| 2025 |
$10.5 billion |
$2,900–$3,200 |
Biosimilar market influences pricing; indication expansion continues. |
| 2026 |
$11.8 billion |
$2,800–$3,100 |
Market penetration of biosimilars; further indication approvals. |
| 2027 |
$13 billion |
$2,700–$3,000 |
Payer negotiations intensify, pressuring prices downward. |
| 2028 |
$14 billion |
$2,600–$2,900 |
Market matures; biosimilar approvals increase competition. |
Market Risks and Opportunities
-
Risks:
- Price erosion due to biosimilars.
- Stringent payer policies decreasing reimbursement rates.
- Regulatory delays on new indications.
-
Opportunities:
- Expansion into new cancer types.
- Development of combination therapies.
- Geographic expansion into emerging markets.
Additional Market Data
- Biosimilars: Expected entry in late 2024–mid 2025, with price discounts of 15–30% compared to the originator.
- Pricing Trends: List prices tend to decline 5% annually, affected by biosimilar competition and policy shifts.
- Insurance and Reimbursement: Reimbursement policies vary; some countries include nivolumab in national formularies with negotiated discounts.
Key Takeaways:
- Nivolumab currently commands a high price driven by its broad indication spectrum and clinical efficacy.
- Patent expirations are poised to introduce biosimilars, likely reducing prices by 15–30% within the next 2–3 years.
- Global sales are projected to continue growth, supported by indication expansion and market penetration, despite price pressures.
- Price per dose in the U.S. ranges $3,200–$3,500, with net price reductions factoring in discounts and negotiations.
- The entry of biosimilars and evolving payer policies are the primary factors influencing future pricing.
FAQs
1. What factors influence nivolumab's pricing trajectory?
Pricing is affected by patent status, biosimilar market entry, indication expansion, payer negotiations, and healthcare policy reforms.
2. How do biosimilars impact rivolumab's market share?
Biosimilars are expected to capture 30–50% of the market share within 2–3 years of entry, reducing list prices by 15–30%.
3. What are key indications driving sales growth?
Melanoma, non-small cell lung cancer, renal cell carcinoma, and head and neck cancers are primary drivers. New indications in gastric, bladder, and other cancers further expand the market.
4. How do reimbursement policies vary across regions?
U.S. payers negotiate discounts, with average net prices 25–35% below list price. Europe and Asia have public healthcare negotiations, often leading to lower prices compared to North America.
5. What is the outlook for price declines over the next five years?
List prices may decline 2–4% annually due to biosimilar competition and negotiations, leading to an approximately 15–30% reduction by 2028 compared to current list prices.
Citations
[1] Bristol-Myers Squibb, "Opdivo (nivolumab) Prescribing Information," 2022.
[2] IQVIA, "2022 Oncology Market Data," 2022.
[3] EvaluatePharma, "Global Oncology Market Forecasts," 2023.
[4] U.S. Medicare Pricing Data, 2022.
[5] Bloomberg Industry Reports, "Biosimilar Entry in Oncology," 2023.
